Skipper Bio Med

Skipper Bio Med is a charitable research consultancy that offers services to assist the preclinical development of theranostics for lung or pancreas cancer

[Skipper Bio Med @SkipperBioMed]

#ASCO2026 highlighted meaninful progress in PDAC. Daraxonrasib delivered strong Phase III results in 2L #PDAC and atebimetinib is heading to Phase III after meeting endpoints in 1L mPDAC. Encouraging signs of innovation in one of oncology's toughest cancers.

[Skipper Bio Med @SkipperBioMed]

@SkipperBioMed will be attending this years Annual @ASCO meeting in Chicago. Feel free to reach out to us if you would like to schedule a meeting. We will see you all there!

[Skipper Bio Med @SkipperBioMed]

@HirshbergFound is now offering up to $75k in grant funding to support basic scientists and clinicians who are working on improving diagnosis and developing new treatment modalities for #PancreaticCancer

Sumission deadline: May 15, 2026

Learn more: https://t.co/lytcDOCP8V

[Skipper Bio Med @SkipperBioMed]

Our team at Skipper Bio Med is proud to support PanCAN PurpleStride, raising funds to advance pancreatic cancer research and support patients and families
Every donation helps move the field forward
Support our team:
https://t.co/02s2Pexhg8
#PancreaticCancer #PurpleStride #PanCAN

[PanTher Therapeutics @PanTherTx]

🎉 Big news! We’ve treated our first participant with PTM-101, an absorbable, long-lasting high-dose chemotherapy patch, in our clinical trial for #PDAC. It’s a huge step toward powerful, localized cancer care for solid #tumors. 🧬

🔗 Full release: https://t.co/DQxbCH1zXg

[Immuneering Corp @Immuneering]

We are proud to sponsor this panel discussion on July 10 hosted by @PanCAN President and CEO @JulieFleshman to share information about the impactful resources offered through the PanCAN Patient Services program to support the #pancreaticcancer community: https://t.co/ZVDJvEM4PL

[Sonnet Bio @SonnetBio]

Our deep knowledge of immune biology is complemented by our extensive drug discovery and development expertise.

$SONN #Oncology #SolidTumors

[Skipper Bio Med @SkipperBioMed]

@TheMarkFdn is now offering $3M in funding over 3 years to fund basic, translational and clinical projects focused on upper GI, GBM, TNBC and #pancreaticcancer. Letters of intent are due September 3rd.

Learn more: https://t.co/HsT53biZ4H

[PanCAN @PanCAN]

Our Chief Scientific and Medical Officer, Dr. @ABerkenblit, and Chief Business Officer, Sudheer Doss recently sat down with Rafael Rosengarten of Genialis for the Talking Precison Medicine Podcast. During the episode, they shared how PanCAN is working across research, clinical development and patient services to drive meaningful progress in the fight against #pancreaticcancer.

🎙️ Catch the full episode here: https://t.co/S5t8p1TPEw

[Skipper Bio Med @SkipperBioMed]

@sgpcri in partnership with @AACR are offering a $1M award to recognize past and current achievments that have significantly advanced #pancreaticcancer reasearch!

Learn more: https://t.co/BwGmBjJBB4

[Skipper Bio Med @SkipperBioMed]

@sgpcri in partnership with @AACR are offering an annual $1M prize that recognizes past and current achievments that have significantly advanced #PancreaticCancer research.

[Pancreatic Cancer Action @OfficialPCA]

💜 Fighting for early diagnosis!

Our founder and spokesperson Ali Stunt spoke at the European Parliament's PANCAID event, advocating for research to develop early detection tools for pancreatic cancer. Let's drive change together.

🔗 Read more: https://t.co/vDqcsnAEfL

[Anna Berkenblit, MD, MMSc @aberkenblit]

This week, I visited Capitol Hill to advocate for federal funding for #pancreaticcancer research with @PanCAN President & CEO @JulieFleshman. Increased, sustained investment is critical to accelerating progress and improving patient outcomes.

[PanCAN @PanCAN]

Cuts to federally funded biomedical research put progress at risk. Pancreatic cancer patients can’t afford to wait. We stand with pancreatic cancer patients, their families and the research community. Learn more and take action at https://t.co/GuCg8kfvqI

[Diane M. Simeone, MD @MadameSurgeon]

Excited to get this collaborative publication out with David Lyden to determine the mechanism by which cancer patients, especially pancreatic cancer patients, get venous thromboembolism via exosome-based expression of integrin beta 2. Check the paper out: https://t.co/OKMHPA9U1X

[FreeMind Group @FreemindGrp]

We are excited to share that we have formed a new partnership with @SkipperBioMed

See Skipper Bio for the webinar details and link: https://t.co/5UbR5fjInb

[Skipper Bio Med @SkipperBioMed]

We are excited to announce a partnership with the Freemind Group! They are highly experienced in securing non-dilutive funding for both academic researchers and companies

Tune in to the webinar on Feb 5 at 10 am ET (link below).
#cancer #grants #research
https://t.co/tJUReGlrM9

[Dana-Farber News @DanaFarberNews]

Join @DanaFarber's Brian Wolpin, MD, MPH, of @DanaFarber_Hale for a discussion on the latest clinical trial research and what's on the horizon in treating #PancreaticCancer. Free virtual event hosted by @PanCAN on Thur 1/30 at 2pm ET.

RSVP today: https://t.co/VzJcTHrrQ2

[Immuneering Corp @Immuneering]

IMM-1-104 Phase 2a #PancreaticCancer data updates in combo with chemo were highlighted this week in @cure_today. Read the full article “IMM-1-104 Treatment May Improve Responses in Pancreatic Cancer” here: https://t.co/30VkbVj7ae
$IMRX

[Immuneering Corp @Immuneering]

January is National #PancreaticCancer #ClinicalTrialsAwarenessMonth! Head over to @PanCan to learn more and register for their free virtual event “Clinical Trials at the Leading Edge of Progress” on Jan 30: https://t.co/x5mocrmudk